Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Peng, Jing  [Clear All Filters]
2023
Liu F, Liang C, Li Z, Zhao S, Yuan H, Yao R, Qin Z, Shangguan S, Zhang S, Zou L-P, et al. Haplotype-specific MAPK3 expression in 16p11.2 deletion contributes to variable neurodevelopment. Brain. 2023.
Fan ZYun, Peng J, Lou JQiao, Chen Y, Wu XMing, Tan R, Tan RXiang. Neuroprotective α-pyrones from Nigrospora oryzae, an endophytic fungus residing in Taxus chinensis var. mairei. Phytochemistry. 2023:113873.
Yao WJinsong, Wang YPeng, Peng J, Yin PPei, Gao H, Xu L, Laux T, Zhang XSheng, Su YHua. The RPT2a-MET1 axis regulates TERMINAL FLOWER1 to control inflorescence meristem indeterminacy in Arabidopsis. Plant Cell. 2023.
Peng J, Yang T, Chen S, Deng N, Luo X, Liao R, Su B. Utilization of hydrogels in mesenchymal stem cell-based therapy for kidney diseases. Tissue Eng Part B Rev. 2023.
2022
Peng J, Mao Z, Liu Y, Tian Y, Leng Q, Gu J, Tan R. 12-Epi-Napelline regulated TGF-β/BMP signaling pathway mediated by BMSCs paracrine acceleration against osteoarthritis. Int Immunopharmacol. 2022;113(Pt A):109307.
Liao J, Li Y, Li X, Su X, Peng J, Xiao N, Fan X, Chen H, Lu G, Lin G, et al. Blood CD4CD25 T regulatory cells constitute a potential predictive marker of subsequent miscarriage in unexplained recurrent pregnancy loss. Int Immunopharmacol. 2022;110:108960.
Xie C, Wang K, Peng J, Jiang X, Pan S, Wang L, Wu Y, Guan Y. Efficacy and safety of human-derived neural stem cell in patients with ischaemic stroke: study protocol for a randomised controlled trial. BMJ Open. 2022;12(11):e055108.
2020
Zhang B, Wang Y, Peng J, Hao Y, Guan Y. Generation of a human induced pluripotent stem cell line from an epilepsy patient carrying mutations in the PIK3R2 gene. Stem Cell Res. 2020;44:101711.
2019
Xiao N, He K, Gong F, Xie Q, Peng J, Su X, Lu Y, Xia X, Lin G, Cheng L. Altered subsets and activities of B lymphocytes in polycystic ovary syndrome. J Allergy Clin Immunol. 2019.
2014
Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 2014.